NCT06239974 Vericiguat in Patients With Coronary Microvascular Dysfunction Causing Stable Chest Pain (V-COM)
| NCT ID | NCT06239974 |
| Status | Recruiting |
| Phase | — |
| Sponsor | The University of Hong Kong |
| Condition | Chest Pain |
| Study Type | INTERVENTIONAL |
| Enrollment | 94 participants |
| Start Date | 2024-09-01 |
| Primary Completion | 2027-08-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 94 participants in total. It began in 2024-09-01 with a primary completion date of 2027-08-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a randomised controlled trial to determine the effectiveness of Vericiguat to improve stress myocardial blood flow (MBF) and myocardial perfusion reserve as measured by cardiac magnetic resonance (CMR) imaging.
Eligibility Criteria
Inclusion Criteria: 1. Stable recurrent chest pain. 2. 40 to 75 years old. 3. Have coronary computed tomography (CT) angiogram or catheter coronary angiogram within 6 months showing non-obstructive coronary artery disease (\<50% coronary artery stenosis or fractional flow reserve \>0.8). 4. Stress CMR MPR \<2.19 12 or Stress MBF \<2.19ml/g/min 13. 5. Female participant is eligible to participate if she is not pregnant or breastfeeding, is not a woman of childbearing potential (WOCBP),or is a WOCBP and agrees to follow contraceptive guidance during the study intervention period and for at least 1 month after the last dose of study intervention. Exclusion Criteria: 1. Systolic blood pressure \<100 mm Hg. 2. Concurrent use of soluble guanylate cyclase stimulators (eg. Riociguat), or phosphodiesterase type 5 inhibitors (eg. vardenafil, tadalafil, and sildenafil). 3. Has known allergy or sensitivity to any soluble guanylate cyclase stimulator. 4. On long-acting nitrates (eg. isosorbide mononitrate) 5. Known cardiomyopathy, complex congenital heart disease, endocarditis or pericarditis. 6. Has acute coronary syndrome (unstable angina, non-ST elevation myocardial infarction (NSTEMI), or ST elevation myocardial infarction (STEMI)) or coronary revascularization (coronary artery bypass grafting (CABG) or percutaneous coronary intervention (PCI)) within 60 days prior to randomisation, or indication for coronary revascularization at time of randomisation. 7. Has symptomatic carotid stenosis, transient ischemic attack (TIA) or stroke within 60 days prior to randomisation. 8. Estimated glomerular filtration rate (eGFR) \<30 mL/min/1.73m2 9. Malignancy or other non-cardiac condition limiting life expectancy to \<3 years. 10. Patient's with implanted devices which are not MRI compatible.
Frequently Asked Questions
Who can join the NCT06239974 clinical trial?
This trial is open to participants of all sexes, aged 40 Years or older, up to 75 Years, studying Chest Pain. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06239974 currently recruiting?
Yes, NCT06239974 is actively recruiting participants. Visit ClinicalTrials.gov or contact The University of Hong Kong to inquire about joining.
Where is the NCT06239974 trial being conducted?
This trial is being conducted at Hong Kong, Hong Kong.
Who is sponsoring the NCT06239974 clinical trial?
NCT06239974 is sponsored by The University of Hong Kong. The trial plans to enroll 94 participants.